Literature DB >> 2052044

The use of intravenous immune globulin in immunodeficiency diseases.

R H Buckley1, R I Schiff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2052044     DOI： 10.1056/NEJM199107113250207

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  58 in total

1.  A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.

Authors:  Melvin Berger
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

2.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

3.  Increased risk of adverse events when changing intravenous immunoglobulin preparations.

Authors:  R Ameratunga; J Sinclair; J Kolbe
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

4.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 5.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

6.  Poliomyelitis-like syndrome following asthmatic attack (Hopkins' syndrome)--recovery associated with i.v. gamma globulin treatment.

Authors:  H A Cohen; A Ashkenasi; H Ring; R Weiss; B Wolach; G Paret; A Barzilai
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells.

Authors:  T R Rhinehart-Jones; A H Fortier; K L Elkins
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

Review 9.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.

Authors:  Mark R Stein; Robert P Nelson; Joseph A Church; Richard L Wasserman; Michael Borte; Christiane Vermylen; Johann Bichler
Journal:  J Clin Immunol       Date:  2008-09-24       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.